HSIC vs IMMX · P/E 24, rev $6.83B vs $640.7M cap
Henry Schein Inc (HSIC) versus Immix Biopharma Inc (IMMX) — a side-by-side from cached financials, not a winner call.
Henry Schein Inc (HSIC) is a medical distribution company listed on NASDAQ.
Immix Biopharma Inc (IMMX) is a biotechnology company listed on US.
Latest reported HSIC revenue for 2026-06-27 was $6.83B. Net income was $201.0M. HSIC currently screens at market cap $9.11B and trailing P/E 24.2.
IMMX does not have a complete income-statement cache yet.
HSIC currently screens at market cap $9.11B and trailing P/E 24.2. IMMX currently screens at market cap $640.7M.
Not investment advice. Open the HSIC and IMMX stock pages for the full models.
Not investment advice.